Thermo Fisher Scientific Inc (TMO)
ÜberbewertetFundamental
61
Kurs
$660.82
Marktkapitalisierung
$250.91B
Teil 1 · Was das Unternehmen wert ist
Übersicht
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilanz & Liquidität
Umsatz
$46.34B
Letzte 12 Monate (bis 27.6.2026)
Nettogewinn
$6.97B
Letzte 12 Monate (bis 27.6.2026)
Freier Cashflow
$6.29B
Gesamtes Eigenkapital
$53.41B
Gesamtverbindlichkeiten
$56.93B
Current Ratio
1.55
Zinsdeckungsgrad
5.46
Schulden/EBITDA
3.62
Gewinn je Aktie
Umsatz & Nettogewinn
Freier Cashflow
Ertragsaufschlüsselung
Historische Aufstellung
Margen im Zeitverlauf
Verschuldung im Zeitverlauf
Wie schwer die Schulden wiegen
Wachstumsraster
Wachstum — Umsatz
Innerer-Wert-Schätzung
Innerer Wert
$437.42
Aktueller Kurs
$660.82
Sicherheitsmarge
-51.1%
Innerer-Wert-Spanne
$284.32 - $590.52
Streubreite zwischen den verwendeten Bewertungsmethoden, kein statistisch kalibriertes Konfidenzintervall.
Bewertungsmethoden
Bewertungskennzahlen
P/E-Verhältnis
36.31
ROE
12.6%
P/B-Verhältnis
4.74
P/FCF
34.11
Bruttomarge
-
ROIC
6.6%
Rentabilitäts-Radar
Wertschöpfung (Wettbewerbsvorteil)
ROIC
6.6%
WACC
8.3%
ROIC − WACC
-1.7 pp
Der ROIC liegt unter den Kapitalkosten: Das Unternehmen vernichtet für jeden investierten Dollar Wert.
Fundamentalanalyse-Kriterien
Bestanden (19)
- EPS shows upward trend
- EPS CAGR 13.95%
- Price CAGR 15.76%
- ROIC 6.6%
- Debt/Equity ratio
- Operating Margin 17.6%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 13.3%
- Revenue Growth 5Y 6.7%
- Analyst Consensus 81% Buy
- Earnings Surprise avg 3.2%
- Earnings Quality (OCF/NI) 1.29
- Share Dilution -1.4%
- Piotroski F-Score 5/9
Nicht bestanden (7)
- P/FCF 34.11
- P/B Ratio 4.74
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- PEG Ratio 16.99
- Net Margin Trend 15.0% vs 15.2%
Nicht verfügbar (2)
- Gross Margin NaN%
- Dividend Payout NaN%
Piotroski F-Score
Gemischte Signale: Einige Bereiche bedürfen Aufmerksamkeit
Gewinnqualität
Hohe Qualität: Gewinne durch Cashflow gedeckt
Aktienverwässerung
Aktienrückkäufe. Aktionärsfreundlich
Institutionelle Beteiligungen
Unternehmensführung
Führungsteam
| Name | Position | Alter |
|---|---|---|
| Mr. Marc N. Casper | Chairman & CEO | 57 |
| Mr. Gianluca Pettiti | President, COO & President of Products and Technologies | 46 |
| Mr. James R. Meyer | Senior VP & CFO | 45 |
| Mr. Joseph R. Holmes | VP & Chief Accounting Officer | 45 |
| Mr. Ryan J. Snyder | Senior VP & Chief Information Officer | - |
| Dr. Karen E. Nelson Ph.D. | Chief Scientific Officer | - |
| Mr. Rafael Tejada | Vice President of Investor Relations | - |
| Mr. Thomas Bailey Shropshire Jr. | Senior VP and General Counsel | - |
| Ms. Sandy B. Pound | VP & Chief Communications Officer | - |
| Mr. Alan J. Malus | Senior Vice President of Strategy & Corporate Development | 65 |
Prüfungsrisiko
2
Vorstandsrisiko
7
Vergütungsrisiko
10
Aktionärsrechterisiko
1
Teil 2 · Der Preis und der Einstiegszeitpunkt
Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.
Dokumente
- Dokument ansehen
Jahresbericht (10-K)
Ein jährlicher Überblick über das Geschäft, die Finanzergebnisse und die Risiken des Unternehmens.
Eingereicht am 2026-02-26
- Dokument ansehen
Quartalsbericht (10-Q)
Ein Update zur finanziellen Entwicklung der letzten drei Monate.
Eingereicht am 2026-07-31
- Dokument ansehen
Ad-hoc-Meldung (8-K)
Eine Mitteilung über ein wichtiges Ereignis, etwa einen Führungswechsel oder eine bedeutende Ankündigung.
Eingereicht am 2026-07-23
via SEC EDGAR
Ertragshistorie
via SEC EDGAR
Latest News
Recent headlines for TMO, sourced from Markets Gazette.
- 5/25/2026POSITIVEIf You Invested $1000 In Thermo Fisher Scientific Stock 20 Years Ago, You Would Have This Much Today
An investment of $1000 in Thermo Fisher Scientific (TMO) stock 20 years ago would have yielded a substantial return, illustrating the company's long-term growth trajectory. While the exact final value is not provided in this snippet, historical performance data suggests significant capital appreciation. This underscores Thermo Fisher's consistent operational success and market leadership in the life sciences and diagnostics sectors. Investors considering TMO should note its history of innovation and strategic acquisitions, which have contributed to its robust financial performance and shareholder value creation over the past two decades.
- 3/12/2026POSITIVEHere's How Much $100 Invested In Thermo Fisher Scientific 15 Years Ago Would Be Worth Today
An investment of $100 in Thermo Fisher Scientific (TMO) 15 years ago would have grown to approximately $1,040 today, representing a substantial 940% return. This performance significantly outpaced the broader market during the same period. The company's consistent growth trajectory, driven by its diversified portfolio in life sciences, diagnostics, and laboratory products, has been a key factor in its stock's appreciation. Investors who held TMO stock have benefited from its strong operational execution and strategic acquisitions, underscoring its resilience and long-term value creation potential.
- 3/2/2026NEUTRALHere's How Much $100 Invested In Thermo Fisher Scientific 20 Years Ago Would Be Worth Today
A retrospective analysis highlights the remarkable performance of Thermo Fisher Scientific, revealing how a $100 investment made two decades ago would have generated substantial returns for today's investors. While this study doesn't provide direct future guidance, it underscores the company's ability to create long-term value, driven by its leadership in life sciences, diagnostics, and research. Consistent growth and innovation have allowed Thermo Fisher to solidify its market position, transforming a modest initial capital into a significantly larger sum. For investors, this serves as a reminder of the importance of patience and selecting companies with strong fundamentals and a lasting competitive advantage.
via Markets Gazette